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Abstract: Imaging-guided photodynamic therapy (PDT) has been regarded as a promising 
strategy for precise cancer treatment. Because of their excellent modifiability and drug loading 
capacity, nanoparticles have played an important role in PDT. However, when traditional 
photosensitizers are made into nanoparticles, both their fluorescence and reactive oxygen 
species (ROS) generation efficiency are decreased due to a phenomenon known as aggregation-
caused quenching. Fortunately, in recent years, several kinds of organic dyes have been 
developed with “abnormal” properties termed aggregation-induced emission (AIE). With 
enhanced fluorescence emission in the nano-aggregation state, the traditional obstacles 
mentioned above could be overcome by AIE luminogens (AIEgens). Herein, we provide a 
better combination of photosensitizers and nanoparticles, a kind of dual-functional AIE 
nanoparticle capable of producing ROS, to achieve targeted and imaging-guided in vivo PDT. 
Good contrast in in vivo imaging and obvious therapeutic efficiency were realized with a low 
dose of AIE nanoparticles as well as a low power density of light, resulting in negligible side 
effects. Our work demonstrates that AIE nanoparticles could play a promising role for imaging-
guided clinical photodynamic cancer therapy in the near future. 
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1 Introduction 
Cancer has increasingly become a primary threat to human health, and more efficient 
treatment methods are urgently needed[1-5]. Conventional cancer treatment methods, 
including surgery, chemotherapy, and radiotherapy, lack accuracy and have significant side 
effects[6-10]. Thus, much attention has been paid to the development of alternative novel 
treatment modalities[11-15]. Imaging-guided photodynamic therapy (PDT) has been 
developed and shown to be an efficient, precise, and non-invasive medical technique for cancer 
therapy[16-20]. The photodynamic effect consists of three elements: a photosensitizer (PS), 
light of a suitable wavelength, and oxygen. Briefly, the energy of the light can be utilized to 
transfer the non-toxic triplet oxygen to toxic reactive oxygen species (ROS). Because the 
process occurs only when both the PS and light of a particular wavelength are present together, 
this method can provide good selectivity for the treatment region[21-23]. Meanwhile, most PSs 
demonstrate fluorescence emission[23, 24], and with the guidance of fluorescence images, 
PDT can be a rather precise treatment modality. 
Along with the development of nanotechnology, various series of colloidal nanoparticles 
have become powerful tools in PDT[25-28]. Since the nanometer scale provides a high surface-
to-volume ratio, nanoparticles can ensure high drug-loading capacity as well as efficient 
surface chemical modification. A high drug-loading capacity leads to fewer side effects, while 
surface chemical modification allows for customized designs, which can greatly improve the 
specific properties of drugs, such as hydrophilicity[29], targeting ability[30-33] etc. In addition, 
the “enhanced permeability and retention” effect, a characteristic of tumor tissue, allows 
nanoparticles to pass through loose vascular tissue and accumulate in the tumor tissue, 
providing a passive way of targeting drug delivery[34, 35]. However, for most PSs, especially 
widely-used porphyrin derivatives, π-π stacking occurs when they are made into nanoparticles, 
due to their hydrophobic and rigid planar structures. This drawback can result in aggregation-
induced quenching of fluorescence[36] and obvious reduction in ROS production[37], which 
limits the performance of optical imaging and the efficiency of imaging-guided PDT. 
Aggregation-induced emission (AIE), an “abnormal” effect discovered in 2001, could 
provide a solution to the dilemma mentioned above[38-40]. Organic propeller-shaped AIE 
luminogens (AIEgens), such as tetraphenylethene (TPE) and silole derivatives, are non-
emissive or weakly-emissive in benign solvents (usually organic solvents) but become much 
brighter when forming aggregates in poor solvents (e.g. water)[41]. Fabricating AIEgens into 
nanoparticles takes advantage of their nature, thus changing the obstacles into opportunity and 
further benefiting photodynamic therapy of tumors. In the field of photodynamic therapy, 
AIEgens have been reported to be combined with commonly used PSs, such as PpIX, acting as 
a sensing probe[42] or an enhancer for ROS production[43, 44]. AIE nanoparticles have also 
been used only as a PS (not a fluorophore) to achieve in vivo PDT via intratumoral injection[45]. 
In these studies, AIEgens were used as a sensing probe, an energy donor, or just a PS. The 
procedures were complex and the potential of AIE materials has only been partially utilized. 
In fact, AIE nanoparticles can be a good photosensitizer as well as a fluorescent label. Recently, 
some AIEgens with the ability to produce ROS themselves have been synthesized and used for 
in vitro PDT treatment[46, 47]. Very recently, a work reported attempts to achieve imaging-
guided and targeted in vivo PDT using AIE nanoparticles alone in a dose of 30 mg/kg[48]. 
While in the present independent work, we have achieved targeted in vivo imaging and a similar 
anti-tumor efficiency (tumor inhibition calculated as 60.4%) with a dose as low as 10 mg/kg, 
which may induce less biological toxicity and side-effects. 
Herein, we fabricated a kind of dual-functional AIE nanoparticle based on a widely-used 
AIEgen, 2-((4-(2,2-bis(4-methoxyphenyl)-1-phenylvinyl)phenyl)(phenyl)methylene) 
malononitrile (TPE-red), which can be easily synthesized and bears the outstanding ability to 
produce ROS[49, 50]. To enhance tumor targeting, promote endocytosis, and ensure a 
therapeutic effect, we modified the nanoparticles with a customized peptide, cyclic (Arg-Gly-
Asp-d-Phe-Cys) (c(RGDfc)), a group commonly used to target over-expressed integrin αvβ3 in 
most cancer cells[51]. As illustrated in Scheme 1B, the polyethylene glycol (PEG) and RGD-
modified TPE-red nanoparticles (TPE-red-PEG-RGD) were intravenously injected into tumor-
bearing mice. It can target the tumor tissues in both passive and active ways, be internalized 
by cancer cells, and finally produce ROS when subjected to suitable irradiation. Compared 
with common PSs, the AIE nanoparticles we fabricated avoid the aggregation-caused 
quenching effect. Taking advantage of bright fluorescence emission, high targeting efficiency, 
and outstanding ability of ROS production, targeted imaging of tumor regions and high anti-
tumor efficiency could be achieved in a rather low dose, which may cause fewer side effect. 
Furthermore, TPE-red-PEG-RGD is rather simple and easy to make compared with composite 
structures, which can facilitate further research and mass production. 
2 Materials and Methods 
2.1 Materials 
All reagents and solvents were purchased from commercially-available sources and used 
without further purification. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N- 
[maleimide (polyethylene glycol)-2000] (DSPE-PEG2000-Mal) was purchased from JenKem 
Technology Co., Ltd. 2- ((4- (2,2-bis(4-methoxyphenyl)-1-phenylvinyl) phenyl) 
(phenyl)methylene) malononitrile (TPE-red) was synthesized according to our previous 
report[49]. Thiolated cyclic (Arg-Gly-Asp-d-Phe-Cys) peptide (c(RGDfc)) was customized 
from GL Biochem Ltd (Shanghai). 9,10-anthracenediylbis (methylene) dimalonic acid (ABDA) 
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased 
from Sigma-Aldrich (Shanghai, China). Minimum essential medium (MEM), dulbecco 
minimum essential media (DMEM), RPMI 1640 medium, fetal bovine serum (FBS), and 
trypsin-EDTA solution were purchased from Gibco. Tetrahydrofuran, dimethyl sulfoxide, 
hydrochloric acid and PBS (1×) were obtained from the Chemical Reagent Department of 
Zhejiang University.  Deionized (DI) water was used in all experiments, with resistivity of 
18.2 MΩ/cm. 
2.2 Preparation of TPE-red-PEG-RGD nanoparticles 
Firstly, TPE-red-PEG nanoparticles were fabricated through a modified nanoprecipitation 
method[52]. Briefly, 0.335 mL of TPE-red solutions in tetrahydrofuran (1 mg/mL) and 0.5 mL 
of DSPE-PEG2000-Mal solutions in tetrahydrofuran (1.2 mg/mL) were mixed gently in a flask 
(25 mL). The mixture was then dried under vacuum in a rotary evaporator at room temperature. 
When the tetrahydrofuran was completely removed, 5 mL of PBS (1×) was added to the flask, 
and the solution was sonicated for several minutes to form an optically-clear suspension.  
To synthesize TPE-red-REG-RGD nanoparticles, the pH value of the as-prepared TPE-red-
PEG nanoparticles solution was adjusted to 5.0~7.0, and then 2 mg c(RGDfc) powder was 
added in a nitrogen atmosphere to start the reaction. The mixture was stirred overnight to make 
them completely react, and the reaction product was washed with deionized water by dialyzing 
for two days. After that, the obtained solution was filtered with 0.22 μm microporous 
membrane, concentrated by vaporizing the water, and finally stored at 4 ℃ for further use. 
2.3 Characterization 
Transmission electron microscopy (TEM) images were taken by a JEOL JEM-1200 
transmission electron microscope operating at 80 kV in bright-field mode. The absorption 
spectra of the nanoparticles were measured with a Shimadzu 2550 UV-vis scanning 
spectrophotometer. The hydrodynamic size distribution of the nanoparticles was measured on 
a Malvern Zetasizer Nano ZS-90. 
2.4 Fluorescence spectra measurement 
As illustrated in Figure S1, a lab-built fluorescence detection system was used to measure 
the one-photon and two-photon fluorescence spectra. Briefly, samples in a cuvette were excited 
by a focused laser beam, and the fluorescence signals were collected laterally by an objective 
lens (20×, NA = 0.75) and recorded with a spectrometer. In the case of one-photon excited 
fluorescence, a 450-nm semiconductor laser was used as the excitation source, and the spectra 
were recorded with a spectrometer of PG 2000, Ideaoptics. In the case of two-photon excited 
fluorescence, a 1040-nm fs laser [from an amplified output of a large-mode-area ytterbium-
doped photonic crystal fiber (PCF) oscillator (1040 nm, 150 fs, 50 MHz)][53]was used as the 
excitation source, and the spectra were recorded with a spectrometer of QE 6500, Ocean Optics. 
2.5 Power dependence of Two-photon fluorescence 
Series of spectra according to different excitation powers were obtained using the method 
described above. Based on the spectra, the intensity of fluorescence was calculated as the 
integral of spectrum envelopes from 500 nm to 670 nm. Then we made a scatter plot of 
fluorescence intensity and the square of incident power, and fitted the points linearly to verify 
the linear relationship between them. 
2.6 Reactive oxygen species (ROS) detection ex vivo 
ABDA was used to evaluate the production of ROS from TPE-red-PEG-RGD. A 200 μL of 
ABDA solution in DMSO was added into a 2 mL aqueous dispersion of TPE-red-PEG-RGD 
(50 μg/mL). The mixture was mixed evenly and irradiated with a 450-nm semiconductor laser. 
The absorption spectra of the mixture were recorded after laser irradiation at various time 
points, and the decrease of absorption value at 378 nm was used as the indicator of ROS. The 
same mixture without laser irradiation was used as a control. 
2.7 In vitro experiments 
2.7.1 Cell culture 
UMUC3 cells (human bladder cancer cell line), Hela cells (human cervical cancer cell line), 
and A549 cells (human pulmonary carcinoma cell line) were obtained from the Cell Culture 
Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences 
(Shanghai, China). The UMUC3 cells, Hela cells, and A549 cells were grown in minimum 
essential medium (MEM), dulbecco minimum essential media (DMEM), and RPMI 1640 
medium, respectively. The culture media were all supplemented with 10% FBS (fetal bovine 
serum), 1% penicillin, and 1% amphotericin B. The environment was kept at 37 ℃ with 5% 
CO2. 
2.7.2 In Vitro cell imaging 
We used the nanoparticle-treated cells to verify the ability of nanoparticles to be swallowed 
by the cells. One day before the treatment, UMUC3 cells, Hela cells and A549 cells were 
seeded in 35-mm cultivation dishes at a confluence of 50 to 60%. During the treatment, the 
cells were incubated with the appropriate concentration of TPE-red-PEG-RGD nanoparticles 
for about 2 hours. Cells treated with PBS were used as a control. Afterwards, the cells were all 
washed thrice with PBS and directly imaged using a microscope. 
Two photon excited fluorescence was utilized to achieve in vitro cell imaging. As illustrated 
in Figure S4, the imaging system consisted of an upright scanning microscope (Olympus, 
BX61+FV1200) equipped with a 1040 nm fs laser [from an amplified output of a large-mode-
area ytterbium-doped photonic crystal fiber (PCF) oscillator (1040 nm, 150 fs, 50 MHz)][53]. 
The 1040 nm fs laser beam was guided into the upright scanning microscope and focused onto 
the cell samples by a 60×/1.00 (Olympus) or a 20×/0.75 (Olympus) water-immersed objective 
lens to achieve two-photon excitation. The signals with an integration time of 10 μs per pixel 
were epi-collected with the same objective lens. After passing through a 590-nm long pass 
filter, a 570-nm dichroic mirror and a 570 nm-625 nm band-pass filter, the fluorescence signals 
were finally detected by a photomultiplier tube (PMT) via non-descanned detection (NDD) 
mode. 
2.7.3 Dark cytotoxicity assay 
In vitro cytotoxicity was measured by performing MTT assays on UMUC3 cells. Cells were 
seeded into a 96-well cell culture plate at 5×103/well and cultured at 37 ℃ with 5% CO2 for 
24h. 200 μL of fresh MEM with different concentrations of TPE-red-PEG-RGD (5, 10, 20, 50 
μg/mL, diluted in MEM) were then added into the wells. The cells were subsequently incubated 
for 48 hours at 37 ℃ with 5% CO2. Then, MTT (20 μL/well, 5 mg/mL) was added to each 
well, and the plate was incubated for an additional 4 hours at 37 ℃ with 5% CO2. The medium 
was then replaced with 200 μL dimethyl sulfoxide (DMSO) per well, and OD570 was 
monitored by an enzyme-linked immune sorbent assay (ELISA) reader.  
2.7.4 Cytotoxicity assay of PDT 
Cells were seeded into a 96-well culture plate at 5×103/well and cultured at 37 ℃ with 5% 
CO2 for 24h. 200 μL fresh MEM with different concentrations of TPE-red-PEG-RGD (10, 20, 
50 μg/mL, diluted in MEM) were then added into the wells. After incubation of 2 hours, the 
nanoparticles-treated cells were irradiated by 450 nm light (40mW, 200mW/cm2) for 6 min per 
well. A control group was irradiated by light, but incubated without nanoparticles. Afterwards, 
the cell viability was measured after incubating for 48 hours with the method introduced above. 
2.8 In vivo experiments 
All in vivo experiments were performed in compliance with Zhejiang University Animal 
Study Committee’s requirements for the care and use of laboratory animals in research. The 
animal housing area (located in Animal Experimentation Center of Zhejiang University) was 
maintained at 24 ℃ with a 12 h light/dark cycle, and animals were fed with water and standard 
laboratory chow. 
2.8.1 Tumor xenograft models 
UMUC3 tumor model was established by the subcutaneous injection of UMUC3 cells 
(5×10% cells/mL) into the selected positions of the male nude mice (5 weeks old, purchased 
from Slaccas Co, Ltd (Shanghai), Chinese Academy of Science). To determine tumor size, the 
greatest length and width of the tumors were determined using a Vernier caliper. The tumor 
volume was calculated as tumor volume = length × width2 × 0.5. 
2.8.2 In vivo fluorescence imaging 
The in vivo fluorescence imaging was performed using Iris Spectrum (Perkin Elmer). When 
tumor volume reached about 50 mm3, 200 μL dispersion of TPE-red-PEG-RGD in 1× PBS (1 
mg/mL) was intravenously injected into the mice. The fluorescence imaging was performed at 
24, 48, and 72 h post-injection. Spectra of fluorescence signals and autofluorescence signals 
were picked from the tail in the experimental group and from the back in the control group, 
respectively. Afterwards, region-of-interests (ROI) were circled around the tumor, and the 
fluorescence intensities were analyzed by Living Image® Software 4.4. A changing tendency 
of the amount of TPE-red-PEG-RGD accumulated in the tumor site was plotted as a time-
varying line chart. 
2.8.3 In vivo PDT treatment 
When tumor volume reached about 50 mm3, 16 tumor-bearing mice were randomly divided 
into four groups. The treatment scheme was as follows: (1) PBS, without irradiation; (2) PBS, 
with irradiation; (3) TPE-red-PEG-RGD (10 mg/kg), without irradiation; (4) TPE-red-PEG-
RGD (10 mg/kg), with irradiation. The photo-irradiation was applied at 1, 2, and 3 days after 
the injection (450 nm, 200mW/cm2, for 20 min). The tumor sizes and body weights were 
inspected every other day for the first 4 days and every day afterwards. The tumor growth 
inhibition rate was calculated using the following formula: 
Tumor growth inhibition rate = (1 – average volume of PDT treated tumors / average volume 
of tumors in control group) ×100% 
The observation lasted for 14 days. Thereafter, the mice were sacrificed, and the tumor 
masses were weighted and then collected together with major organs for H&E staining. 
2.9 Histological Examinations 
The collected tumors and major organs were fixed in 10% formalin, embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin. The histological sections were imaged 
under an inverted optical microscope for analysis. 
Statistics 
All results presented are mean ± s.d. Statistical analysis was performed using Student’s t-test. 
(*P< 0.05, **P< 0.01, and ***P< 0.001). 
 
3 Results and Discussion 
3.1 Synthesis and characterizations of TPEred-PEG-RGD 
We synthesized TPE-red according to our previous report[49]. The entire procedure to 
fabricate our nanoparticles was illustrated as Scheme 1A. Firstly, we encapsulated TPE-red 
with a kind of biocompatible amphiphilic polymer 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine-N- [maleimide (polyethylene glycol)-2000] (DSPE-PEG2000-Mal)[54, 
55], recorded as TPE-red-PEG. The long PEG chains were used to reduce the phagocytosis of 
nanoparticles by the reticuloendothelial system (RES) [56, 57]. We then modified the target 
moiety c(RGDfc) through click chemistry between –SH and maleimide at the surface of TPE-
red-PEG, yielding TPE-red-PEG-RGD. The morphology and the cross-section structure of 
TPE-red-PEG-RGD were first checked by transmission electron microscopy (TEM) (Figure 
1A). The average size of the nanoparticles was about 50 nm, which was confirmed by dynamic 
light scattering (DLS) (insert in Figure 1A). The absorption spectra of TPE-red in 
tetrahydrofuran (THF) solution and TPE-red-PEG-RGD in PBS are shown in Figure 1B. We 
find that, compared with the absorption spectrum of TPE-red, the spectrum of TPE-red-PEG-
RGD keeps the same shape but has a slight red-shift in wavelength due to the encapsulation 
process. The fluorescence spectra were recorded using a lab-built fluorescence detection 
system (Figure S1). We adjusted the absorption of both TPE-red and TPE-red-PEG-RGD to 
the same value and measured the spectra under the same conditions. As can be seen from 
Figure 1C, with the same location of the peak at 650 nm, the fluorescence of TPE-red-PEG-
RGD is much stronger than that of TPE-red, which confirms the AIE nature of the materials. 
Meanwhile, we also compared the fluorescence emitting ability of TPE-red-PEG-RGD and 
nanoparticles of a common PS, chlorin e6. Figure S2 shows that, with the same concentration 
of 100 μg/mL, the fluorescence of TPE-red-PEG-RGD was obviously stronger than that of 
chlorin e6 nanoparticles, which indicates the advantage of TPE-red-PEG-RGD over traditional 
PSs. We then verified the ability of TPE-red-PEG-RGD to produce ROS by using a common 
ROS probe, 9,10-anthracenediylbis (methylene) dimalonic acid (ABDA)[58]. Under 
irradiation of 450 nm continuous wave (CW) laser light, when mixed with TPE-red-PEG-RGD, 
the absorption of ABDA at 377 nm kept decreasing over 40 minutes and dropped to about 70 % 
of the original value (Figure 1D, Figure S3C). At the same time, almost no change could be 
observed in control groups (Figure 1D, Figure S3A, S3B). This phenomenon indicated that 
the TPE-red-PEG-RGD has strong ability to produce ROS continuously under light irradiation. 
3.2 In Vitro cell imaging 
The targeting and endocytosis ability of TPE-red-PEG-RGD were verified by two-photon 
excited fluorescence cell imaging. We first studied the two-photon excited fluorescence 
properties of TPE-red-PEG-RGD; the spectra were recorded using our lab-built system (see 
the “Methods” section and Figure S1, Figure 2A), and power dependence fitting furtherly 
confirmed the nonlinear optical process (Figure 2B). We utilized a scanning microscope to 
achieve two-photon excited fluorescence imaging. The signal was excited by a 1040 fs laser 
[from an amplified output of a large-mode-area ytterbium-doped photonic crystal fiber (PCF) 
oscillator (1040 nm, 150 fs, 50 MHz)][53] and collected by an objective lens. Figure 2C and 
2D show the cell images of UMUC3 cells (human bladder cell line) using a 20× objective lens 
without and with TPE-red-PEG-RGD (0.2μg/mL), respectively. Almost all of the cells were 
labeled. We also performed cell imaging with a 60× objective lens to verify the label details, 
and we could clearly find that the signal points distribute well around the nucleus (Figure 2E). 
Furthermore, we compared the endocytosis ability of TPE-red-PEG-RGD using a 20× 
objective lens with different cell lines (Figure S5), which showed the outstanding ability of 
TPE-red-PEG-RGD on labelling different cancer cells. 
3.3 MTT assay 
A methyl thiazolyltetrazolium (MTT) assay was performed to study the cytotoxicity under 
dark conditions and the PDT efficiency of TPE-red-PEG-RGD[59]. As shown in Figure 3A, 
TPE-red-PEG-RGD was found to have low toxicity in the dark, and the relative cell viability 
is kept above 90 % even with a concentration of 50 μg/mL. Upon the irradiation with 450 nm 
laser light at a power density of 200 mW/cm2, UMUC3 cells without TPE-red-PEG-RGD 
showed no difference compared to the control group, while the relative cell viability of cells 
incubated with the nanoparticles dropped below 50 % and decreased as concentration increased, 
as shown in Figure 3B. These phenomena indicate that TPE-red-PEG-RGD is minimally-toxic 
in the dark and much more toxic under 450 nm light. 
3.4 In vivo fluorescence imaging 
To explore the in vivo tumor targeting and labeling capability of TPE-red-PEG-ROS, we 
used tumor-bearing mice as a tumor xenograft model. The UMUC3 cell line was chosen 
because of its high degree of malignity and representativeness[60, 61]. TPE-red-PEG-RGD in 
PBS (1×) was intravenously injected, and in vivo images were captured at 24h, 48h, and 72h 
post-injection. We chose a mouse with a strip-shaped tumor to make the label more 
distinguishable, and the bright field photograph is shown in Figure 4A. Fluorescence images 
at 24h (Figure 4B), 48 h (Figure 4C), and 72 h (Figure 4D) together with the bright field 
image show that TPE-red-PEG-RGD can label tumor tissues well and last for at least 72 h 
(Figure 4F). The signal from the tumor site was obviously higher than that from peripheral 
tissue except for the RES (e.g. liver, spleen, etc.) and lymph, and the shape of the labeled area 
coincidences well with that of the tumor. Spectra taken from the injection port on the tail and 
the back of the mouse in the control group also confirmed that the fluorescence signal is 
strongly distinguishable from tissue autofluorescence (Figure 4E). With knowledge of organ 
distributions and metabolic processing of nanoparticles, the liver, spleen, and lymph can be 
easily recognized, and the additional labeled areas can be determined to be tumor tissue. That 
will guide us the exact region to apply PDT. 
3.5 In vivo PDT treatment 
To further assess the in vivo antitumor efficiency of TPE-red-PEG-RGD, 16 tumor-bearing 
mice were randomly divided into four groups and applied with different treatments: (1) PBS, 
without irradiation; (2) PBS, with irradiation; (3) TPE-red-PEG-RGD (10 mg/kg), without 
irradiation; (4) TPE-red-PEG-RGD (10 mg/kg), with irradiation. The observation lasted for 14 
days. Thereafter, the mice were sacrificed and photographs were taken of them and the tumors, 
shown in Figure 5C and 5D, respectively. We recorded the change of tumor volumes. It could 
be found that only when both TPE-red-PEG-RGD and 450 nm laser light were present could 
the growth of the tumor volume be obviously inhibited (P<0.001) (Figure 5A), and the tumor 
growth inhibition rate was calculated to be as high as 60.4 %. From Figure 5B, we could find 
that the final average tumor weight of the PDT-treated group was significantly lower than the 
three other control groups (P<0.05). The therapeutic efficiency was also confirmed by the 
tumor tissue sections. Only tumors that were treated with both TPE-red-PEG-RGD and 450-
nm-light irradiation have obvious signs of cell death, while nothing of significance happened 
to tumors in other groups (Figure 6). 
3.6 In vivo toxicity 
To evaluate the in vivo toxicity of TPE-red-PEG-RGD, the weight of the mice was recorded 
during the treatment. As shown in Figure S6, all of mice grew healthily, and not much 
difference can be observed. We also checked the sections of major organs in different treatment 
groups; no obvious inflammation or abnormalities could be found, which indicated negligible 
in vivo toxicity of TPE-red-PEG-RGD (Figure 7). 
 
4 Conclusion 
In summary, we demonstrated dual-functional TPE-red-PEG-RGD to achieve targeted and 
imaging-guided in vivo photodynamic therapy. Our work has the following advantages: 1) 
TPE-red-PEG-RGD takes advantage of the AIE nature of TPE-red molecules and enhance the 
fluorescence signals instead of suffering from aggregation-caused quenching like many 
commonly used PSs; 2) both passive and active targeting were utilized to guarantee therapeutic 
efficiency, and targeted imaging of tumor regions and high anti-tumor efficiency could be 
achieved with a reasonably low dose, which may cause fewer side effects; 3) the structure of 
TPE-red-PEG-RGD is simple and easy to fabricate, which could benefit further research and 
mass production. Our research results show the promising role of AIE nanoparticles in 
imaging-guided in vivo PDT, both in biomedical research and clinical applications.  
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 Scheme 1. Schematic illustration of (A) the fabrication procedure of TPE-red-PEG-RGD and 
(B) the process of targeting and image-guided in vivo photodynamic cancer therapy with 
intravenous injection. 
 Figure 1. Characteristics of TPE-red-PEG-RGD. (A) TEM image of TPE-red-PEG-RGD 
(insert: DLS data); (B) absorption spectra and (C) fluorescent spectra of TPE-red-PEG-RGD 
in PBS (1×) and TPE-red in THF; (D) Normalized absorption of ABDA at 377 nm with 
different treatments. 
 
 Figure 2. Two-photon excitation property and in vitro cell imaging of UMUC3 cells incubated 
with TPE-red-PEG-RGD. (A) Two-photon excited fluorescence spectrum of TPE-red-PEG-
RGD; (B) the power dependence relationship and linear fitting of the data; two-photon excited 
fluorescence images of UMUC3 cells (C) without nanoparticle treatment using a 20× objective 
lens and (D), (E) treated with TPE-red-PEG-RGD (0.2 μg/mL) using a 20× objective lens and 
a 60× objective lens, respectively. Scale bar, 50 μm. 
 Figure 3. Viability of UMUC3 cells treated with various concentrations of TPE-red-PEG-RGD, 
(A) without and (B) with irradiation. The blue arrows indicate the presence of light. Error bars 
indicate SD. 
 
 Figure 4. In vivo imaging studies of tumor bearing mice treated with TPE-red-PEG-RGD. (A) 
Photograph of mice in the control group (left) and experimental group (right); (B)-(D) 
fluorescence images of mice 24, 48, and 72 h post-injection in control group (left) and 
experimental group (right); (E) spectra of TPE-red-PEG-RGD (taken from injection port on 
tail) and tissue autofluorescence (taken from the back of a mouse in the control group); (F) 
Changing tendency of total radiant efficiency in the tumor area (circled in blue). Error bars 
indicate SD. 
 
 
Figure 5. In vivo anti-tumor study of TPE-red-PEG-RGD. (A) Change of average tumor 
volume with different treatments as time passed (blue arrows indicate the presence of light); 
(B) Average tumor weights with different treatments at 14 days; Photographs of (C) sacrificed 
mice and (D) tumors. The numbers written on the paper indicate different groups: 1) PBS, no 
irradiation; 2) PBS, irradiation; 3) TPE-red-PEG-RGD, no irradiation; 4) TPE-red-PEG-RGD, 
irradiation (PDT). Error bars indicate SD. Scale bar, 50 μm. (*P<0.05, **P<0.01) 
 
 
Figure 6. H&E stained sections of tumor tissues in different treatment groups. Scale bar, 50 μm. 
 
 
Figure 7. H&E stained sections of major organs (heart, liver, spleen, lung, and kidney) of mice 
with different treatments. The numbers written on the paper indicate different groups: 1) PBS, 
no irradiation; 2) PBS, irradiation; 3) TPE-red-PEG-RGD, no irradiation; 4) TPE-red-PEG-
RGD, irradiation (PDT). Scale bar, 50 μm. 
 
 
